Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:12
|
作者
Chen, Zhen-Ping [1 ]
Li, Pei-Jing [1 ]
Li, Gang [1 ]
Tang, Ling [1 ]
Zhen, Ying-Zi [1 ]
Wu, Xin-Yi [1 ]
Cheng, Xiao-Ling [1 ]
Luke, Koon Hung [2 ,3 ,4 ]
Blanchette, Victor S. [5 ]
Poon, Man-Chiu [6 ,7 ,8 ]
Ding, Qiu-Lan [9 ]
Wu, Run-Hui [1 ]
机构
[1] Capital Med Univ, Natl Key Discipline Pediat, Beijing Key Lab Pediat Hematol Oncol, Hematol Oncol Ctr,Beijing Childrens Hosp,Minist E, Beijing 100045, Peoples R China
[2] Childrens Hosp Eastern Ontario, Dept Pediat & Lab Med, Ottawa, ON K1H 8L1, Canada
[3] Childrens Hosp Eastern Ontario, Hemophilia Clin, Ottawa, ON K1H 8L1, Canada
[4] Univ Ottawa, Ottawa, ON K1H 8L1, Canada
[5] Univ Toronto, Res Inst, Hosp Sick Children, Dept Pediat & Child Hlth Evaluat Sci,Div Hematol, Toronto, ON M5G 1X8, Canada
[6] Univ Calgary, Foothills Hosp, Dept Med Pediat & Oncol, Calgary, AB T2N 2T9, Canada
[7] Univ Calgary, Foothills Hosp, Southern Alberta Rare Blood & Bleeding Disorders, Calgary, AB T2N 2T9, Canada
[8] Calgary Hlth Reg, Calgary, AB T2N 2T9, Canada
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai 200025, Peoples R China
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics; DOSE SECONDARY PROPHYLAXIS; RECOMBINANT FACTOR-VIII; HALF-LIFE; FVIII; CHILDREN; RECOVERY; EFFICACY; PLASMA;
D O I
10.4103/0366-6999.233604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China. Methods: A total of 36 boys (plasma-derived [pd]-FVIII, n = 15; recombinant [r] FVIII, n = 21) were enrolled between January 2015 and May 2016 in Beijing Children's Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion). Results: The mean FVIII half-life (t(1/2)) was 10.99 +/- 3.45 h (range 5.52-20.02 h), the mean in vivo recovery (IVR) was 2.01 +/- 0.42 IU/dl per rU/kg (range 1.24-3.02 IU/l per IU/kg) and mean clearance (CL) of FVIII is 4.34 +/- 1.58 ml'kg(-1) h(-1) (range 2.29-7.90 ml.kg(-1) h(-1)). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R-2 = 0.32, P < 0.01). The t(1/2) of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF: Ag) also was associated with FVIII half-life (R-2 = 0.52, P < 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 +/- 0.68 h vs. 12.3 +/- 0.79 h, t = 2.70, P = 0.01). The FVIII IR correlated with age (R-2 = 0.21, P < 0.01) and VWF: Ag level (R-2 = 0.28, P < 0.01). CL rates were faster in young patients and in those with low-VWF: Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 +/- 0.38 vs. 4.00 +/- 0.32 ml.kg(-1) h(-1), t = 2.53, P = 0.02). Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF: Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1781 / U28
页数:6
相关论文
共 50 条
  • [21] Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review
    Hassan, S. .
    Cannavo, A.
    Gouw, S. C.
    Rosendaal, F. R.
    van der Bom, J. G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (06) : 1055 - 1068
  • [22] Factor VIII Products and Inhibitor Development in Severe Hemophilia A
    Gouw, Samantha C.
    van der Bom, Johanna G.
    Ljung, Rolf
    Escuriola, Carmen
    Cid, Ana R.
    Claeyssens-Donadel, Segolene
    van Geet, Christel
    Kenet, Gili
    Makipernaa, Anne
    Molinari, Angelo Claudio
    Muntean, Wolfgang
    Kobelt, Rainer
    Rivard, George
    Santagostino, Elena
    Thomas, Angela
    van den Berg, H. Marijke
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (03) : 231 - 239
  • [23] Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
    Lissitchkov, Toshko
    Willemze, Annemieke
    Jan, Christelle
    Zilberstein, Moshe
    Katragadda, Suresh
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (04)
  • [24] Iliopsoas hematoma in patients with hemophilia:: A single-center study
    Dauty, Marc
    Sigaud, Marianne
    Trossaert, Marc
    Fressinaud, Edith
    Letenneur, Joseph
    Dubois, Charles
    JOINT BONE SPINE, 2007, 74 (02) : 179 - 183
  • [25] Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
    Konkle, Barbara A.
    Stasyshyn, Oleksandra
    Chowdary, Pratima
    Bevan, David H.
    Mant, Tim
    Shima, Midori
    Engl, Werner
    Dyck-Jones, Jacqueline
    Fuerlinger, Monika
    Patrone, Lisa
    Ewenstein, Bruce
    Abbuehl, Brigitt
    BLOOD, 2015, 126 (09) : 1078 - 1085
  • [26] Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged &lt;12 years with severe hemophilia A
    Huang, Kun
    Zhen, Yingzi
    Li, Gang
    Wu, Xinyi
    Wu, Runhui
    Chen, Zhenping
    HAEMOPHILIA, 2021, 27 (03) : E340 - E346
  • [27] Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A
    Wu, Runhui
    Wang, Xiaoling
    Zhao, Xielan
    Cheng, Yanli
    Zhou, Zeping
    Sun, Jing
    Xu, Ming
    Li, Wenqian
    Xiao, Jianwen
    Yang, Fenge
    Chen, Yun
    Xu, Weiqun
    Huang, Jing
    Ma, Chuanrong
    Gai, Wenlin
    Xie, Liangzhi
    Yang, Renchi
    HAEMOPHILIA, 2022, 28 (06) : E199 - E208
  • [28] Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study
    Janbain, Maissa
    Enjolras, Nathalie
    Bordet, Jean-Claude
    Bolbos, Radu
    Brevet, Marie
    Leissinger, Cindy
    Dargaud, Yesim
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (03) : 584 - 592
  • [29] Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh
    Tory, Sanzina Sadia
    Ghosh, Sujan
    Nazneen, Humayra
    Farhad, Nurul
    Islam, Salwa
    Hasan, Mohammad Jahid
    Biswas, Akhil Ranjan
    EJHAEM, 2024, 5 (01): : 39 - 46
  • [30] FACTOR-VIII GENE INVERSIONS IN SEVERE HEMOPHILIA-A PATIENTS
    VANDEWATER, NS
    WILLIAMS, R
    NELSON, J
    BROWETT, PJ
    PATHOLOGY, 1995, 27 (01) : 83 - 85